NCT04939090
Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic leptomeningeal disease or known brain metastases; Patients with a hormone-sensitive tumor
https://ClinicalTrials.gov/show/NCT04939090